Stryker Corp.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8636671013
USD
364.35
-1.6 (-0.44%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Stryker Corp. stock-summary
stock-summary
Stryker Corp.
Pharmaceuticals & Biotechnology
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. Its segments include Orthopaedics, MedSurg, Neurotechnology and Spine. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. Its products include implants, which are used in joint replacement and trauma surgeries, and other products. It offers musculoskeletal care and sensor technology for total joint replacement.
Company Coordinates stock-summary
Company Details
2825 Airview Blvd , PORTAGE MI : 49002-1802
stock-summary
Tel: 1 269 3892600
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 209 Schemes (27.87%)

Foreign Institutions

Held by 538 Foreign Institutions (18.97%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Kevin Lobo
Chairman of the Board, Chief Executive Officer
Mr. Allan Golston
Lead Independent Director
Dr. Giovanni Caforio
Director
Ms. Mary Brainerd
Independent Director
Dr. Srikant Datar
Independent Director
Dr. Roch Doliveux
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
6,022 Million
(Quarterly Results - Jun 2025)
Net Profit:
884 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 150,289 Million (Large Cap)

stock-summary
P/E

34.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.84%

stock-summary
Debt Equity

0.67

stock-summary
Return on Equity

21.38%

stock-summary
Price to Book

7.09